Analysis of clinical characteristics and prognosis of patients with newly diagnosed mul-tiple myeloma with thrombocytopenia
10.12354/j.issn.1000-8179.2024.20240572
- VernacularTitle:初诊多发性骨髓瘤血小板减少患者临床特征及预后分析
- Author:
Qin XIAOQI
1
;
Xia LING
;
Niu YUANMAN
;
Xie XINNA
;
Wang SHIFANG
;
Guo QIAOHUA
;
Ma YANPING
Author Information
1. 山西医科大学第二医院血液科(太原市 030001)
- Keywords:
multiple myeloma(MM);
thrombocytopenia;
prognosis
- From:
Chinese Journal of Clinical Oncology
2024;51(12):607-610
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical characteristics and prognosis of patients with newly diagnosed multiple myeloma(NDMM)with thrombocytopenia.Methods:Clinical data of 529 patients with NDMM admitted to The Second Hospital of Shanxi Medical University between January 2012 and December 2021 were retrospectively analyzed.The patients were categorized into thrombocytopenia and nor-mal platelet count groups based on their platelet count levels.Results:A total of 529 patients with NDMM were included in this study,with 108(20.42%)patients in the thrombocytopenia group.The median progression-free survival(mPFS)was 30.64 months(95%confidence in-terval[CI]:23.43-37.85)in the thrombocytopenia group,which was shorter than that in the normal platelet count group(41.39 months[95%CI:37.37-45.39],P=0.002).The median overall survival(mOS)was 40.59 months(95%CI:30.61-50.57)in the thrombocytopenia group,which was shorter than that in the normal platelet count group(60.92 months[95%CI:54.54-67.29],P<0.001).Multivariate Cox regression analysis identified thrombocytopenia as a risk factor for OS in patients with NDMM(HR=1.238[95%CI:1.16-1.952],P=0.03).Conclusions:The prognosis of patients with NDMM with thrombocytopenia was worse than that of patients with NDMM who had normal platelet levels.Thrombocytopenia may serve as a poor prognostic indicator for NDMM.
